natgillin/translations-raw huggingface dataset:
The catalyst unit according to anyone of claims 1 to 6, wherein the blocks have a number of cells per cm, which can be the same or different, from 3 to 10 and wherein the number of pores per cm of the foamed layer is 4 to 20. 
Katalizatorska jedinica u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačena time, da blokovi imaju broj stanica po centimetru, koji mogu biti isti ili različiti za svaki od blokova u katalitičkoj jedinici, od 3 do 10 i pri čemu je broj pora po centimetru pjenastog sloja od 4 do 20.
and The antibody for use of claim 1, wherein the amount of anti-sclerostin antibody administered is from 1 mg/kg to 3 mg/kg. 
Protutijelo ili fragment za upotrebu u skladu s patentnim zahtjevom 1, naznačeno time, da je količina protutijela protiv sklerostina koja se primjenjuje od 1 mg/kg do 3 mg/kg.
The antibody for use of claim 1 or 2, wherein the amount of anti-sclerostin antibody administered is about 3 mg/kg. 
Protutijelo ili fragment za upotrebu u skladu s patentnim zahtjevom 1 ili 2, naznačeno time, da je količina protutijela protiv sklerostina koja se primjenjuje oko 3 mg/kg.
The antibody for use of claim 1, where the method comprises administering a dose of from 70 to 450 mg. 
Protutijelo ili fragment za upotrebu u skladu s patentnim zahtjevom 1, naznačeno time, da postupak obuhvaća davanje protutijela protiv sklerostina čovjeku u dozi od 70 do 450 mg.
The antibody for use of claim 1, where the method comprises administering a dose of about 210 mg. 
Protutijelo ili fragment za upotrebu u skladu s patentnim zahtjevom 1, naznačeno time, da postupak obuhvaća davanja doze od oko 210 mg.
A chondroitin sulphate according to claim 1 obtained by chemical sulphation and subsequent acid or radical depolymerisation of the capsular polysaccharide K4 of E. coli after removal of the fructose residues by means of hydrolysis. 
Kondroitin-sulfat prema patentnom zahtjevu 1, naznačen time da je dobiven kemijskim sulfoniranjem a zatim kiselinskom ili radikalskom depolimerizacijom kapsularnog polisaharida K4 od E. coli nakon uklanjanja ostataka fruktoze pomoću hidrolize.
A chondroitin sulphate according to claim 1 obtained by chemical sulphation of the low-molecular-weight natural fraction of the capsular polysaccharide K4 of E. coli carried out after removal of the fructose residues by means of hydrolysis. 
Kondroitin-sulfat prema patentnom zahtjevu 1, naznačen time da je dobiven kemijskim sulfoniranjem prirodne frakcije kapsularnog polisaharida K4 od E. coli male molekulske mase provedeno nakon uklanjanja ostataka fruktoze pomoću hidrolize.
Chondroitin sulphate of claims 1-5 for use in the prevention and treatment of acute or chronic inflammatory conditions and/or for the preservation of musculoskeletal health in humans and animals. 
Kondroitin-sulfat iz patentnih zahtjeva 1-5 za upotrebu u sprječavanju i liječenju akutnih ili kroničnih upalnih stanja i/ili za održavanje koštano-mišićnog zdravlja kod ljudi i životinja.
Compositions according to claim 8 wherein the other active ingredients are selected from glucosamine hydrochloride, glucosamine sulphate, N-acetyl-glucosamine, hyaluronic acid, amino acids, collagen, hydrolysed collagen, polyunsaturated fatty acids, keratin, dermatin, methylsulphonylmethane (MSM), folates, reduced folates, vitamins, group B vitamins, S-adenosylmethionine (SAMe), ascorbic acid or manganese ascorbate. 
Pripravci prema patentnom zahtjevu 8, naznačeni time da su druge aktivne tvari odabrani od sljedećih: glukozamin-hidroklorid, glukozamin-sulfat, N-acetil-glukozamin, hijaluronska kiselina, aminokiseline, kolagen, hidrolizirani kolagen, polinezasićene masne kiseline, keratin, dermatin, metilsulfonilmetan (MSM), folati, reducirani folati, vitamini, skupina B vitamina, S-adenozilmetionin (SAMe), askorbinska kiselina ili manganov askorbat.
Compositions according to claim 8 or 9 in the form of capsules, soft gel capsules, tablets, drinks in liquid form or drinks in powder form to be dissolved. 
Pripravci prema patentnom zahtjevu 8 ili 9 u obliku kapsula, mekih gel kapsula, tableta, napitaka u tekućem obliku ili napitaka u obliku praška za otapanje.
The use of a compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a disease selected from Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA) and myasthenia gravis. 
Upotreba spoja prema bilo kojem od patentnih zahtjeva 1 do 18, ili njegove farmaceutski prihvatljive soli, za pripremanje lijeka za liječenje bolesti odabrane od Amiotrofne Lateralne Skleroze (ALS), Spinalne Mišićne Atrofije (SMA) i mijastenije gravis.
The compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof, for use in a method of treatment of a disease selected from Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA) and myasthenia gravis. 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 18, ili njegova farmaceutski prihvatljiva sol, za upotrebu u postupku liječenja bolesti odabrane od Amiotrofne Lateralne Skleroze (ALS), Spinalne Mišićne Atrofije (SMA) i miastenije gravis.
Device (1) for transporting a child, such as a pram and/or buggy, comprising: a first wheel-bearing arm (2), an end of which is connected in bearing-mounted manner to a first wheel (3) and another end of which is fixedly connected to a coupling housing (4); 
Uređaj (1) za transport djeteta, kao što su kolica za novorođenče i/ili dječja kolica, koji sadrži: prvi krak koji nosi kotač (2), čiji je kraj spojen na način postavljanja s ležajem na prvi kotač (3) i čiji je drugi kraj fiksno spojen na spojno kućište (4);
a push bar (7',7") for pushing the device along, which push bar is coupled pivotally at an end to the coupling housing; 
prečku za guranje (7', 7") za guranje uređaja naprijed, navedena prečka za guranje je zakretno spojena na kraju na spojno kućište;
a connector device (10) comprising a connector element (11) configured for releasable coupling to a supporting device (21) for a child such as a carrycot, a child's seat or a car seat; 
spojnu napravu (10) koja sadrži spojni element (11) konfiguriranu za odvojivo spajanje na potporni uređaj (21) za dijete kao što je nosiljka, dječja sjedalica ili sjedalica za automobil;
Device as claimed in any of the foregoing claims, wherein the connector device (10) is configured such that, in the collapsed position, the supporting device is or can be coupled in a direction away from the device (1). 
Uređaj prema bilo kojem od prethodnih zahtjeva, naznačen time da je spojna naprava (10) konfigurirana tako da je, u sklopljenom položaju, potporni uređaj spojen ili može biti spojen u smjeru suprotnom od uređaja (1).
Device as claimed in any of the foregoing claims, wherein the connector element (11) comprises two mutually pivotable parts (12, 13), wherein one part (12) is pivotally connected to the first arm and the second part (13) can be coupled to the supporting device, and wherein the two parts are pivotally connected for inward rotation of the second part. 
Uređaj prema bilo kojem od prethodnih zahtjeva, naznačen time da spojni element (11) sadrži dva međusobno zakretna dijela (12, 13), pri je čemu jedan dio (12) zakretno spojen na prvi krak i drugi dio (13) se može spojiti na potporni uređaj, te pri čemu su dva dijela zakretno spojena radi rotiranja drugog dijela prema unutra.
Device as claimed in any of the foregoing claims, wherein the device (1) comprises a pair of first and second arms disposed parallel relative to each other and a pair of push bars (7',7") disposed parallel relative to each other, wherein the pair of first arms and the pair of second arms are each mutually connected by means of separate transverse connections. 
Uređaj prema bilo kojem od prethodnih zahtjeva, naznačen time da uređaj (1) sadrži par prvih i drugih krakova raspoređenih paralelno jedan u odnosu na drugog i par prečki za guranje (7', 7") raspoređenih paralelno jedna u odnosu na drugu, pri čemu su par prvih krakova i par drugih krakova svaki međusobno povezani pomoću odvojenih poprečnih spojeva.
Assembly for transporting a child, comprising the device as claimed in any of the claims 1-14 and a supporting device for a child such as a carrycot, a child's seat or a car seat, which supporting device can be coupled to the device by means of the connector element (11) of the device. 
Sklop za transport djeteta, naznačen time sadrži uređaj prema bilo kojem od zahtjeva 1-14 i potporni uređaj za dijete kao što je nosiljka, dječja sjedalica ili sjedalica za automobil, navedeni potporni uređaj može biti spojen na uređaj pomoću spojnog elementa (11) uređaja.
The catalyst unit according to anyone of claims 1 to 3, wherein the density of the cells of the honeycomb blocks ranges from 3 to 10 cells/cm and the density of the pores of the foamed material is of 4 to 20 pores/cm. 
Katalizatorska jedinica u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time, da je gustoća stanica saćastih blokova u rasponu od 3 do 10 stanica po centimetru, a gustoća pora pjenastog materijala je od 4 do 20 pora po centimetru.
The catalyst unit according to anyone of claims 1 to 6, wherein the blocks have a number of cells per cm, which can be the same or different for each of the blocks in the catalytic unit, from 3 to 10 and wherein the number of pores per cm of the foamed layer is 4 to 20. 
Katalizatorska jedinica u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačena time, da blokovi imaju broj stanica po centimetru, koji mogu biti isti ili različiti za svaki od blokova u katalitičkoj jedinici, od 3 do 10 i pri čemu je broj pora po centimetru pjenastog sloja od 4 do 20.
The method for waterproofing and draining off seeped water according to claim 1, characterised by performing the drainage valve device (13) comprising a geomembrane sheet chosen from the following materials: thermoplastic materials, thermoplastic rubbers, thermoset materials, bituminous materials. 
Postupak za hidroizolaciju i drenažu infiltrirane vode u skladu s patentnim zahtjevom 1, naznačen time, da se koristi ventil za drenažu (13) koji se sastoji od geomembranskih ploča odabranih od sljedećih materijala: termoplastičnih materijala, termoplastičnih guma, termo materijala, bitumenskih materijala.
The method for waterproofing and draining off seeped water, according to claim 5, characterised in that the layer of draining material is selected from a geonet, a geospacer, or combination thereof. 
Postupak za hidroizolaciju i drenažu infiltrirane vode u skladu s patentnim zahtjevom 5, naznačen time, da je sloj drenažnog materijala odabran iz materijala geonet, geospacer ili njihove kombinacije.
The apparatus of claim 1, wherein, when the intra prediction mode is a planar mode, the reference pixels of a prediction block are generated using a corner reference pixel, a left reference pixel and an upper reference pixel. 
Uređaj iz zahtjeva 1, pri čemu se, kada je intrapredikcijski režim planarni režim, referentni pikseli predikcijskog bloka generiraju pomoću kutnog referentnog piksela, lijevog referentnog piksela i gornjeg referentnog piksela.
A (2' R)-2'-deoxy-2'-fluoro-2'- C -methyl nucleoside (β-D) of claim 1 or a pharmaceutically acceptable salt thereof of the formula: 
(2'R)-2'-deoksi-2'-fluoro-2'-C-metil nukleozid (β-D) iz patentnog zahtjeva 1 ili njegova farmaceutski prihvatljiva sol formule: [image]
a reference pixel generator (240) configured to generate reference pixels corresponding to unavailable reference pixels and to adaptively filter the reference pixels according to an intra prediction mode; 
generator referentnih piksela (240) konfiguriran za generiranje referentnih piksela koji odgovaraju nedostupnim referentnim pikselima i za adaptivno filtriranje referentnih piksela u skladu s intrapredikcijskim režimom;
is hydrogen, together with R15 a -CH2 group or a double bond; 
b je vodik, zajedno s R7b je -CH2 skupina; ili dvostruka veza;
comprising the oxidation of a compound of formula la in which R6a, R6b, R7a, R7b, R9, R10, R11, R15, R16 have the same meaning as in formula IIa, characterized in that the oxidation is performed with at least 3 molar equivalents of alkali hypochlorite, organic hypochlorite or 2-3 molar equivalents of alkaline-earth hypochlorite as an oxidizing agent in the presence of catalytic amounts of a 2,2,6,6-tetramethylpiperidine-N-oxide derivative at a pH of at least 8.0, in a two-phase solvent-water mixture, whereby the solvent is selected such that both the TEMPO derivative and the compounds of formula la can be well dissolved therein. 
reakciju spojeva s formulom Ia [image] u kojoj a, R6b, R7a, R7b, R9, R10, R11, R15, R16 imaju isto značenje kao u formuli IIa, s najmanje 3 molarna ekvivalenta alkalijskog hipoklorita, organskog hipoklorita ili najmanje 2 molarna ekvivalenta zemnoalkalijskog hipoklorita kao oksidacijskog sredstva u prisutnosti katalitičkih količina derivata 2,2,6,6-tetrametilpiperidin-N-oksida kod pH od najmanje 8.0, u dvofaznoj smjesi otapalo-voda, pri čemu je otapalo odabrano tako da se oba TEMPO derivat i spojevi s formulom Ia u njemu mogu dobro otopiti, tako da nastane spoj s formulom IIa; i
The formulation according to claim 3, wherein the further coating comprises at least one cellulose derivative selected from the group consisting of hydroxypropylcellulose and ethylcellulose. The formulation according to claim 3, wherein the further coating is made of a 1:9 to 9:1 weight ratio mixture of a methacrylic acid and ethyl acrylate copolymer and an ethyl acrylate and methyl methacrylate copolymer. 
Formulacija u skladu s patentnim zahtjevom 8, pri čemu sloj polimera koji se otapa na način neovisan o pH sadrži najmanje jedan derivat celuloze odabran iz grupe koja se sastoji od hidroksipropilceluloze ili etilceluloze ili je načinjen od 1:9 do 9:1, poželjno 2:8 do 3:7, smjese kopolimera metakrilne kiseline i etil akrilata i kopolimera etil akrilat metil metakrilata.
The honeycomb structure according to claim 3, wherein the blocks have a number of cells per cm, which can be the same or different, from 3 to 10 and wherein the number of pores per cm of the foamed layer is 4 to 20. 
Katalizatorska jedinica u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačena time, da blokovi imaju broj stanica po centimetru, koji mogu biti isti ili različiti za svaki od blokova u katalitičkoj jedinici, od 3 do 10 i pri čemu je broj pora po centimetru pjenastog sloja od 4 do 20.
The solid oral dosage form according to any one of the preceding claims 1 to 2, wherein the tablet is a roller compacted tablet. 
Čvrsti oralni dozni oblik prema zahtjevu 1, naznačen time, da spomenuta tableta je formulacija s brzim oslobađanjem.
The pharmaceutical composition for use according to any one of the preceding claims, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy (PSP), multiple system atrophy (MSA), Lewy body dementia, Parkinson's disease dementia, epilepsy, stroke, Huntington's Chorea, cerebral hypoxia, multiple sclerosis, and peripheral neuropathy. 
Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da neurodegenerativna bolest je odabrana iz skupine koju čine Alzheimerova bolest, Parkinsonova bolest, progresivna supranuklearna paraliza (PSP), multipla sistemska atrofija (MSA), demencija s Lewyjevim tjelešcima, Parkinsonova bolest s demencijom, epilepsija, kap, Huntingtonova korea, cerebralna hipoksija, multipla skleroza, te periferna neuropatija.
The pharmaceutical composition for use according to claim 5, wherein peripheral neuropathy is associated with diabetes mellitus. 
Farmaceutski pripravak za uporabu prema zahtjevu 5, naznačen time da je periferna neuropatija povezana s dijabetes melitusom.
The pharmaceutical composition for use according to claim 5, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, and stroke. 
Farmaceutski pripravak za uporabu prema zahtjevu 5, naznačen time da neurodegenerativna bolest je odabrana iz skupine koju čine Alzheimerova bolest, Parkinsonova bolest,, i kap.
The pharmaceutical composition for use according to claim 5, wherein the Alzheimer's disease is an early-stage Alzheimer's disease. 
Farmaceutski pripravak za uporabu prema zahtjevu 5, naznačen time da Alzheimerova bolest je Alzheimerova bolest u ranoj fazi.
The pharmaceutical composition for use according to claim 5, wherein the Parkinson's disease is an early-stage Parkinson's disease. 
Farmaceutski pripravak za uporabu prema zahtjevu 5, naznačen time da Parkinsonova bolest je Parkinsonova bolest u ranoj fazi.
is a single or double bond; 
• je jednostruka ili dvostruka veza;
-L2-A1-L1- is one of the following: wherein 
L2-A1-L1- je jedno od sljedećeg:
-L2-A1-L1- is one of the following: or 
L2-A1-L1- je jedno od sljedećeg:
--L2-A1-L1- is optionally substituted with 1-4 Rx groups and is one of the following: 
L2-A1-L1- je po izboru supstituiran s 1-4 Rx skupine i jedno je od sljedećeg:
is a covalent bond or an optionally substituted methylene; 
je kovalentna veza ili po izboru supstituirani metilen;
Ring A3 is an optionally substituted phenyl or optionally substituted pyridinyl ring; 
Prsten A3 je po izboru supstituirani fenil ili po izboru supstituirani piridinil prsten;
A pharmaceutical composition containing a compound of claim 1 and a pharmaceutically acceptable excipient, or a pharmaceutical composition containing a compound of claim 16 and a pharmaceutically acceptable excipient. 
Farmaceutski pripravak koji sadrži spoj prema zahtjevu 1 i farmaceutski prikladnu pomoćnu tvar, ili farmaceutski pripravak koji sadrži spoj prema zahtjevu 16 i farmaceutski prikladnu pomoćnu tvar.
provided that the following compound is excluded: 
uz uvjet da je slijedeći spoj isključen: [image]
The pharmaceutical composition according to claim 31, further comprising one or more other suitable therapeutic agents selected from: a dipeptidyl peptidase-IV inhibitor, a sodium-glucose transporter-2 inhibitor and a 11b-HSD-1 inhibitor. 
Farmaceutska kompozicija prema patentnom zahtjevu 31, koja dalje sadrži jedno ili više drugih pogodnih terapeutskih sredstava izabranih od: inhibitora dipeptidil peptidaze-IV, inhibitora transportera 2 natrij glukoze i inhibitora 11b-HSD-1.
Topical ophthalmic composition selected from the group of eye drops, ointments and unguents, said composition containing somatostatin or a somatostatin analogue selected from the group formed by somatostatin-28, somatostatin-14, somatostatin-13, prosomatostatin, octreotide, lanreotide, vapreotide, pasireotide, seglitide, cortistatin and their pharmaceutically acceptable salts, for use in the treatment and/or prevention of a posterior segment eye disease selected from the group formed by nonproliferative diabetic retinopathy, proliferative diabetic retinopathy, retinal neovascularization, ischemia-induced retinopathy, retinopathy of prematurity, sickle-cell retinopathy, retinal vein occlusion, retinitis pigmentosa, uveitis, macular edema and cystoid macular edema by topical ocular administration, characterized in that the concentration of somatostatin or somatostatin analogue in said composition ranges between 1 µg/mL and 10 mg/mL. 
Topikalna očna kompozicija izabrana iz grupe koji čine kapi za oči, masti i melemi, s time što sadrži somatostatin ili neki analog somatostatina izabran iz grupe koju čine somatostatin-28, somatostatin-14, somatostatin-13, prosomatostatin, oktreotid, lanreotid, vapreotid, pasireotid, seglitid, kortistatin i njihove farmaceutski prihvatljive soli, za primjenu u terapiji i/ili prevenciji bolesti stražnje očne komore, među kojima su ne-proliferativna dijabetska retinopatija, proliferativna diabetska retinopatija, neovaskularizacija mrežnice, iskemijska retinopatija, retinopatija nedonoščadi, retinopatija uslijed anemije srpastih okluzija retinalne vene, retinitis pigmetnoza, uveitis, otok makule i cistoidni otok makule primjenom topikalnog tretmana, naznačenog time što se koncentracija somatostatina ili analoga somatostatina u toj kompoziciji nalazi u opsegu od 1 µg/mL do 10 mg/mL.
A topical ophthalmic composition for use according to claim 2, characterized in that the eye drop vehicle is an isotonic aqueous solution, a poly(vinyl alcohol) aqueous solution or mixtures thereof. 
Topikalna očna kompozicija za primjenu u skladu sa zahtjevom 2, naznačena time što je nosač otopine kapi za oči neka izotonična vodena topina, neka poli(vinil-alkoholna) vodena otopina ili njihova smjesa.
A process for preparing a compound represented by formula 4, or a phosphorous-based diastereomer thereof: wherein P* represents a chiral phosphorus atom, and wherein said phosphorous-based diastereomer is represented by formula R P- 4 or S P- 4: which comprises: 
Proces za pripremanje spoja koji je predstavljen formulom 4, ili dijastereomera toga spoja na bazi fosfora: [image] gdje P* predstavlja hiralni atom fosfora, i gdje je navedeni dijastereomer na bazi fosfora predstavljen formulom RP-4 ili SP-4: [image] koji obuhvaća:
reacting an isopropyl-alanate, A, a di-X'-phenylphosphate, B, 2'-deoxy-2'-fluoro-2'-C-methyluridine, 3, and a base to obtain a first mixture comprising 4, or the phosphorous-based diastereomer thereof; wherein X is a conjugate base of an acid, n is 0 or 1, and X' is a halogen 
reagiranje izopropil-alanata, A, di-X'-fenilfosfata, B, 2'-deoksi-2'-fluor-2'-C- metiluridina, 3, i baze da bi se dobila prva smjesa koja sadrži 4, ili dijastereomer toga spoja na bazi fosfora; [image] gdje je X konjugirana baza kiseline, n je 0 ili 1, i X' je halogen
reacting the first mixture with a protecting compound to obtain a second mixture comprising 4, or the phosphorous-based diastereomer thereof, wherein the protecting compound is selected from a t-butyldimethylsilyl protecting compound and a dimethoxytriphenylmethyl protecting compound; and 
reagiranje prve smjese sa zaštitnim spojem da bi se dobila druga mješavina koja sadrži 4, ili dijastereomer toga spoja na bazi fosfora, gdje je zaštitni spoj odabran od t-butildimetilsilil zaštitnog spoja i dimetoksitrifenilmetil zaštitnog spoja; i
The process as claimed in claim 2, wherein A is anhydrous. 
Proces prema patentnom zahtjevu 2, gdje A je anhidriran.
dissolving or suspending the second mixture or the purified R P- 4 in a solvent; 
rastvaranje ili suspendiranje druge smjese ili pročišćenog RP-4 u otapalu;
adding sufficient anti-solvent to obtain crystalline R P- 4 . 
dodavanje dovoljnog anti-otapala da se dobije kristalni RP-4.
dissolving or suspending the second mixture or the purified S P- 4 in a solvent followed by seeding with crystalline S P- 4 at room temperature; 
rastvaranje ili suspendiranje druge smjese ili pročišćenog SP-4 u otapalu što je praćeno formiranjem kristala sa SP-4 na sobnoj temperaturi;
dissolving or suspending the first solid in a solvent at its reflux temperature; and 
rastvaranje ili suspendiranje prve čvrste supstance u otapalu na njegovoj temperaturi refluksa; i
cooling or adding an anti-solvent to obtain a second solid. 
hlađenje ili dodavanje anti-otapala da se dobije druga čvrsta supstanca.
dissolving or suspending the second mixture or the purified S P- 4 in a first solvent followed by adding an anti-solvent so as to obtain a first composition in which the residual solvent/anti-solvent is removed by decanting to obtain a residue; 
rastvaranje ili suspendiranje druge smjese ili pročišćenog SP-4 u prvom otapalu praćeno dodavanjem anti-otapala tako da se dobije prva kompozicija u kojoj je preostalo otapalo/anti-otapalo uklonjeno dekantiranjem da bi se dobio talog;
dissolving or suspending the first solid using a second solvent so as to obtain a third composition; 
rastvaranje ili suspendiranje prve čvrste supstance korištenjem drugog otapala tako da se dobije treća kompozicija;
dissolving or suspending the second solid in a third solvent, optionally heated to the reflux temperature of the third solvent to obtain a fourth composition, and, if necessary, and 
rastvaranje ili suspendiranje druge čvrste supstance u trećem otapalu, po izboru ugrijane do temperature refluksa trećeg otapala kako bi se dobila četvrta kompozicija, i, ako je potrebno, i